FDA Grants Fast Track Designation to Oncoprex Combination for NSCLC

Oncoprex in combination with osimertinib received fast track designation from the FDA to treat patients with non-small cell lung cancer.

Source: CancerNetwork - January 21, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news